MedTrace Logo

Pulmonary and Systemic Hepatocyte Growth Factors in Patients With COPD

NCT00477074 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 44

Last updated 2007-05-22

No results posted yet for this study

Summary

The role of HGF and KGF in COPD is poorly known. Plantier et al found that cultured fibroblasts harvested from patients with emphysema produced less HGF (but similar amounts of KGF) than controls, and Bonay et al found a direct relationship between the severity of airflow obstruction and HGF mRNA content in lung samples of smokers. These two studies suggest, therefore, that the pulmonary regulation of HGF may be abnormal in patients with COPD. However, both HGF and KGF can also be released by extra-pulmonary organs, thus having the potential to act systemically. Given the current clinical relevance attributed to the systemic effects of COPD, in this study we compared the levels of HGF and KGF in the pulmonary (bronchoalveolar lavage (BAL) fluid) and systemic compartment (circulating blood) of smokers with and without COPD and never smokers.

Conditions

Interventions

PROCEDURE

bronchoalveolar lavage, blood analysis

Sponsors & Collaborators

  • Sociedad Española de Neumología y Cirugía Torácica

    collaborator OTHER

  • Fundacion Caubet-Cimera Islas Baleares

    collaborator OTHER

  • Hospital Universitari Son Dureta

    lead OTHER

Principal Investigators

  • Jaume Sauleda · Hospital Universitari Son Dureta

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-01-31
Completion
2005-12-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00477074 on ClinicalTrials.gov